Ed Arce
Stock Analyst at WestPark Capital
(3.93)
# 635
Out of 4,984 analysts
470
Total ratings
45.71%
Success rate
12.05%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Ed Arce
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ENTA Enanta Pharmaceuticals | Initiates: Buy | $24 | $7.45 | +222.15% | 12 | Sep 2, 2025 | |
| TVTX Travere Therapeutics | Assumes: Buy | $30 | $22.77 | +31.75% | 21 | Jun 11, 2025 | |
| MTVA MetaVia | Reiterates: Buy | $12 | $1.33 | +802.26% | 3 | Apr 16, 2025 | |
| UNCY Unicycive Therapeutics | Reiterates: Buy | $75 | $3.99 | +1,779.70% | 27 | Apr 11, 2025 | |
| ARCT Arcturus Therapeutics Holdings | Reiterates: Buy | $60 | $18.09 | +231.67% | 31 | Apr 10, 2025 | |
| AKBA Akebia Therapeutics | Reiterates: Buy | $7.5 | $2.83 | +165.02% | 36 | Apr 4, 2025 | |
| IVA Inventiva | Reiterates: Buy | $13 | $5.32 | +144.36% | 16 | Apr 2, 2025 | |
| GALT Galectin Therapeutics | Reiterates: Neutral | n/a | $4.41 | - | 17 | Apr 2, 2025 | |
| TLPH Talphera | Reiterates: Buy | $6 | $0.98 | +512.24% | 6 | Apr 1, 2025 | |
| ALGS Aligos Therapeutics | Reiterates: Buy | $70 | $8.95 | +682.12% | 6 | Mar 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $20.55 | - | 8 | Mar 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $240 | $4.17 | +5,655.40% | 17 | Mar 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $1.53 | - | 24 | Mar 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $32 | $6.20 | +416.13% | 11 | Mar 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $24 → $35 | $64.71 | -45.91% | 22 | Mar 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $72 → $75 | $42.60 | +76.06% | 25 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $29 → $21 | $7.97 | +163.49% | 22 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $66 → $72 | $73.79 | -2.43% | 30 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $400 → $405 | $427.05 | -5.16% | 17 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $5.5 | $6.42 | -14.33% | 9 | Feb 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $95 | $29.48 | +222.25% | 6 | Feb 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $13 | $4.30 | +202.33% | 18 | Feb 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $5 | $4.40 | +13.64% | 18 | Jan 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $48 | $24.52 | +95.76% | 2 | Jan 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $7.5 | $7.30 | +2.74% | 11 | Dec 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $5 | $0.68 | +636.05% | 13 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $13 | $12.52 | +3.83% | 16 | Sep 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | n/a | $1.74 | - | 8 | Mar 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $25 | $24.76 | +0.97% | 8 | Dec 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.48 | - | 4 | May 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $18.12 | - | 2 | Nov 18, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $7 | $23.69 | -70.45% | 1 | Nov 10, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $21 | $35.62 | -41.04% | 1 | Sep 11, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $2.97 | - | 2 | Feb 15, 2017 |
Enanta Pharmaceuticals
Sep 2, 2025
Initiates: Buy
Price Target: $24
Current: $7.45
Upside: +222.15%
Travere Therapeutics
Jun 11, 2025
Assumes: Buy
Price Target: $30
Current: $22.77
Upside: +31.75%
MetaVia
Apr 16, 2025
Reiterates: Buy
Price Target: $12
Current: $1.33
Upside: +802.26%
Unicycive Therapeutics
Apr 11, 2025
Reiterates: Buy
Price Target: $75
Current: $3.99
Upside: +1,779.70%
Arcturus Therapeutics Holdings
Apr 10, 2025
Reiterates: Buy
Price Target: $60
Current: $18.09
Upside: +231.67%
Akebia Therapeutics
Apr 4, 2025
Reiterates: Buy
Price Target: $7.5
Current: $2.83
Upside: +165.02%
Inventiva
Apr 2, 2025
Reiterates: Buy
Price Target: $13
Current: $5.32
Upside: +144.36%
Galectin Therapeutics
Apr 2, 2025
Reiterates: Neutral
Price Target: n/a
Current: $4.41
Upside: -
Talphera
Apr 1, 2025
Reiterates: Buy
Price Target: $6
Current: $0.98
Upside: +512.24%
Aligos Therapeutics
Mar 31, 2025
Reiterates: Buy
Price Target: $70
Current: $8.95
Upside: +682.12%
Mar 24, 2025
Reiterates: Neutral
Price Target: n/a
Current: $20.55
Upside: -
Mar 19, 2025
Reiterates: Buy
Price Target: $240
Current: $4.17
Upside: +5,655.40%
Mar 18, 2025
Reiterates: Neutral
Price Target: n/a
Current: $1.53
Upside: -
Mar 13, 2025
Reiterates: Buy
Price Target: $32
Current: $6.20
Upside: +416.13%
Mar 10, 2025
Maintains: Buy
Price Target: $24 → $35
Current: $64.71
Upside: -45.91%
Mar 3, 2025
Maintains: Buy
Price Target: $72 → $75
Current: $42.60
Upside: +76.06%
Feb 28, 2025
Reiterates: Buy
Price Target: $29 → $21
Current: $7.97
Upside: +163.49%
Feb 28, 2025
Maintains: Buy
Price Target: $66 → $72
Current: $73.79
Upside: -2.43%
Feb 27, 2025
Maintains: Buy
Price Target: $400 → $405
Current: $427.05
Upside: -5.16%
Feb 21, 2025
Reiterates: Neutral
Price Target: $5.5
Current: $6.42
Upside: -14.33%
Feb 18, 2025
Reiterates: Buy
Price Target: $95
Current: $29.48
Upside: +222.25%
Feb 7, 2025
Reiterates: Buy
Price Target: $13
Current: $4.30
Upside: +202.33%
Jan 21, 2025
Reiterates: Buy
Price Target: $5
Current: $4.40
Upside: +13.64%
Jan 14, 2025
Reiterates: Buy
Price Target: $48
Current: $24.52
Upside: +95.76%
Dec 4, 2024
Reiterates: Neutral
Price Target: $7.5
Current: $7.30
Upside: +2.74%
Sep 10, 2024
Reiterates: Buy
Price Target: $5
Current: $0.68
Upside: +636.05%
Sep 6, 2024
Reiterates: Buy
Price Target: $13
Current: $12.52
Upside: +3.83%
Mar 20, 2024
Upgrades: Neutral
Price Target: n/a
Current: $1.74
Upside: -
Dec 27, 2023
Reiterates: Buy
Price Target: $25
Current: $24.76
Upside: +0.97%
May 3, 2022
Downgrades: Neutral
Price Target: n/a
Current: $1.48
Upside: -
Nov 18, 2020
Downgrades: Neutral
Price Target: n/a
Current: $18.12
Upside: -
Nov 10, 2017
Assumes: Buy
Price Target: $7
Current: $23.69
Upside: -70.45%
Sep 11, 2017
Initiates: Buy
Price Target: $21
Current: $35.62
Upside: -41.04%
Feb 15, 2017
Downgrades: Neutral
Price Target: n/a
Current: $2.97
Upside: -